New Delhi: Drug firm Ranbaxy Laboratories on Monday declined to comment on the reports from Brussels that European Union anti-trust regulators may fine the domestic pharma company for allegedly blocking of entry of cheaper generic medicines in the market.
Reports said that Ranbaxy was among the nine companies that are to fined for the allegedly blocking the entry of the generic medicines in the EU.
When contacted, a Ranbaxy spokesperson said: "We will not like to offer any comments at this point".
The reports also named Denmark's Lundbeck, Merck KGaA, Generics UK, Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma and AL Industriers.
Shares of Ranbaxy Laboratories on Monday closed at Rs 362.35 apiece on BSE, down 3.49 per cent from their previous close.
First Published: Monday, June 03, 2013, 20:57